Pipeline
ModeX focuses on cancers and infectious diseases where multispecific medicines and vaccines show potential.
modextherapeutics.comCrawled Nov 14, 2026
ModeX focuses on cancers and infectious diseases where multispecific medicines and vaccines show potential.
Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans Candidate showed
Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205
Provides Initial $59 Million and up to $168 Million Contingent on Milestones NATICK, Mass. – September 28, 2023 – ModeX Therapeutics Inc., an OPKO
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKO Dr.
Please click here to view a recording of the March 20th R&D Day presentations. MIAMI, March 09, 2023 – OPKO Health, Inc. (NASDAQ: OPK) today announced
ModeX’s MDX-2201 targets multiple Epstein-Barr virus (EBV) proteins using its biologics platform.
Dr. John Mascola joined ModeX Therapeutics as Chief Scientific Officer in 2022. He is an accomplished physician-scientist, virologist and immunologist,
Dr. Elias Zerhouni co-founded ModeX Therapeutics and is Chairman of the Board. Dr. Zerhouni started his academic career in biomedical imaging and
Dr. Ji Zhang is Chief Operating Officer of ModeX Therapeutics. He was most recently Senior Partner and Senior Vice President of Enterprise R&D
Dr. Kerry Culm is Chief Development Officer at ModeX, responsible for the clinical development of novel multispecific therapeutics for immuno-oncology and
Lana DeAngelis is the Head of HR at ModeX, leading overall people operations and talent optimization strategy, employee experience and development, and
Zhi-yong Yang is Head of Discovery Research at ModeX. Previously, he served as the Director of the Vector Core laboratory within the Vaccine Research
Introducing OPKO Health
ModeX’s platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency against complex diseases.
ModeX develops multispecific biologics by combining natural protein structures to address diseases driven by multiple pathways.
ModeX’s modular platforms combine multiple biologics into single molecules to treat complex diseases.
Read Privacy Policy for ModeX Therapeutics
Read Terms of Service for ModeX Therapeutics